Search - tctmd.com

Displaying 321 - 340 of 1865

Sort: Relevancy | Date

News Conference News TCT 2021

Conservative Management, Careful Diagnosis Key for Good SCAD Outcomes

Yael L. Maxwell

November 09, 2021

Presentation TCT 2021

Antiplatelet Therapy Is Sufficient for DRT Prevention After LAAC

Presenter: Jacqueline Saw

November 06, 2021

News Conference News TCT 2021

Magnetic Endoscopy Capsule Reveals GI Damage Surprises From Antiplatelets

Caitlin E. Cox

November 06, 2021

Presentation TCT 2021

Evidence-Based Antiplatelet and Antithrombotic Therapy for TAVR

Presenter: Stephan Windecker

November 05, 2021

News Conference News TCT 2021

More DAPT Duration Data, More Calls to Tailor to Individual Patients

Shelley Wood

November 05, 2021

Presentation TCT 2021

Case #2: Antiplatelet Therapy Disruption Challenges After Stenting

Presenter: George Dangas

November 05, 2021

Presentation TCT 2021

Case #1: Bleeding and Ischemic Complications from the EXCEL Trial

Presenter: Gregg Stone

November 05, 2021

Presentation TCT 2021

Finding the Sweet Spot: Balancing Reducing Ischemic Risk and Reducing Bleeding Risk with Antiplatelet Therapy

Presenter: Deepak Bhatt

November 05, 2021

Presentation TCT 2021

When to Shorten DAPT: Key Messages

Presenter: George Dangas

November 05, 2021

Presentation TCT 2021

Antiplatelet Therapy for Patients with Diabetes Undergoing PCI

Presenter: Deepak Bhatt

November 05, 2021

Presentation TCT 2021

Introduction

Presenter: George Dangas

November 05, 2021

News Conference News TCT 2021

PRAGUE-17: LAA Occlusion Noninferior to DOACs Over Longer Term

Todd Neale

November 05, 2021

Presentation TCT 2021

MASTER-DAPT: A Randomized Trial of Abbreviated Antiplatelet Therapy - Outcomes in High Bleeding Risk Patients With High Thrombotic and Ischemic Risk

Presenter: Pieter Smits

November 05, 2021

News Conference News TCT 2021

OCT Guidance Cuts Stent Use in STEMI Without Plaque Rupture: EROSION III

Shelley Wood

November 04, 2021

News Conference News TCT 2021

‘Sweet Like SUGAR’: Polymer-Free Stent Noninferior to ZES in Diabetic Patients

Yael L. Maxwell

November 04, 2021

News Conference News TCT 2021

FAVOR III China Adds Strength to Value of QFR-Guided PCI

L.A. McKeown

November 04, 2021

News Conference News TCT 2021

De-escalating Prasugrel Reduces Net Events in Complex PCI for ACS

Yael L. Maxwell

October 22, 2021

News Daily News

USPSTF at Last Takes Tougher Stance on Aspirin in Primary Prevention

Shelley Wood

October 15, 2021

News Daily News

Half-Dose DOAC May Be a Good Post-Watchman Option

Todd Neale

October 14, 2021

Antithrombotic therapy does not provide a benefit for clinically stable but symptomatic outpatients with COVID-19, published results of the ACTIV-4b trial affirm. Neither aspirin nor apixaban (Eliquis; Bristol Myers Squibb) at prophylactic or therapeutic doses reduced what were already very low rates of major adverse cardiopulmonary outcomes versus placebo, and both modestly increased bleeding, researchers led by Jean Connors, MD (Brigham and Women’s Hospital, Boston, MA), report in a paper published online

News Daily News

ACTIV-4b: No Antithrombotic Therapy Needed for COVID-19 Outpatients

Todd Neale

October 13, 2021

Advertisement

Conservative Management, Careful Diagnosis Key for Good SCAD Outcomes

Antiplatelet Therapy Is Sufficient for DRT Prevention After LAAC

Magnetic Endoscopy Capsule Reveals GI Damage Surprises From Antiplatelets

Evidence-Based Antiplatelet and Antithrombotic Therapy for TAVR

More DAPT Duration Data, More Calls to Tailor to Individual Patients

Case #2: Antiplatelet Therapy Disruption Challenges After Stenting

Case #1: Bleeding and Ischemic Complications from the EXCEL Trial

Finding the Sweet Spot: Balancing Reducing Ischemic Risk and Reducing Bleeding Risk with Antiplatelet Therapy

When to Shorten DAPT: Key Messages

Antiplatelet Therapy for Patients with Diabetes Undergoing PCI

Introduction

PRAGUE-17: LAA Occlusion Noninferior to DOACs Over Longer Term

MASTER-DAPT: A Randomized Trial of Abbreviated Antiplatelet Therapy - Outcomes in High Bleeding Risk Patients With High Thrombotic and Ischemic Risk

OCT Guidance Cuts Stent Use in STEMI Without Plaque Rupture: EROSION III

‘Sweet Like SUGAR’: Polymer-Free Stent Noninferior to ZES in Diabetic Patients

FAVOR III China Adds Strength to Value of QFR-Guided PCI

De-escalating Prasugrel Reduces Net Events in Complex PCI for ACS

USPSTF at Last Takes Tougher Stance on Aspirin in Primary Prevention

Half-Dose DOAC May Be a Good Post-Watchman Option

ACTIV-4b: No Antithrombotic Therapy Needed for COVID-19 Outpatients

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content